<DOC>
	<DOCNO>NCT00002913</DOCNO>
	<brief_summary>Phase I trial study effectiveness paclitaxel , cisplatin , topotecan without filgrastim treat patient newly diagnose stage III stage IV epithelial ovarian cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy</brief_summary>
	<brief_title>Paclitaxel , Cisplatin , Topotecan With Without Filgrastim Treating Patients With Newly Diagnosed Stage III Stage IV Epithelial Ovarian Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dos paclitaxel , cisplatin , topotecan administer together without filgrastim ( G-CSF ) patient newly diagnose advanced ovarian cancer . II . Describe quantitate clinical toxic effect combination chemotherapy paclitaxel , cisplatin , topotecan without G-CSF . III . Assess preliminary evidence antitumor activity combination chemotherapy patient . OUTLINE : This dose escalation study topotecan . Patients receive paclitaxel IV 3 hour cisplatin IV day 1 , follow topotecan IV 30 minute day 1-3 . Patients receive filgrastim ( G-CSF ) subcutaneously begin day 4 continue blood count recover . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 4-6 patient receive escalate dos topotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow clinically indicate .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Endometrioid</mesh_term>
	<mesh_term>Cystadenocarcinoma</mesh_term>
	<mesh_term>Brenner Tumor</mesh_term>
	<mesh_term>Cystadenocarcinoma , Serous</mesh_term>
	<mesh_term>Cystadenocarcinoma , Mucinous</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Histologically confirm epithelial ovarian carcinoma No borderline ovarian carcinoma Stage III/IV disease suboptimally optimally debulked The following histology eligible : Adenocarcinoma ( unspecified ) Mucinous cystadenocarcinoma Clear cell adenocarcinoma Serous cystadenocarcinoma Endometrioid adenocarcinoma Transitional cell carcinoma Malignant Brenner 's tumor Undifferentiated carcinoma Mixed epithelial carcinoma Extraovarian papillary serous cystadenocarcinoma Measurable evaluable disease Performance status GOG 01 Enabling completion least 2 course therapy Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 1.5 mg/dL Creatinine clearance least 60 mL/min No myocardial infarction within 6 month No congestive heart failure No unstable uncontrolled angina No history cardiac arrhythmia require antiarrhythmia medication No uncontrolled hypertension No hypersensitivity E. coliderived drug preparation No active infection No sensory neuropathy No malignancy within past 5 year except nonmelanomatous skin cancer No prior chemotherapy No prior radiotherapy Recovered recent surgery</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>